Effect of escitalopram and sertraline on inflammatory factors,NSE and NPY in patients with post-stroke depression
-
摘要: 目的 脑卒中后抑郁不仅会加重患者脑卒中症状,同时还会增加患者精神上的痛苦,严重威胁患者生命安全,为了减轻患者的抑郁症状,增强预后效果,发掘更好的药物治疗十分重要,因此本研究通过探讨艾司西酞普兰与舍曲林对脑卒中后抑郁患者疗效及对炎症因子、NSE、NPY的影响为临床提供依据。 方法 选取2015年3月—2016年10月浙江省立同德闲林分院脑卒中后抑郁患者98例,采用随机数字表法分为观察组和对照组,各49例。观察组患者在常规治疗的基础上加用艾司西酞普兰进行治疗,对照组患者在常规治疗的基础上加用舍曲林进行治疗,2组患者均治疗8周。观察2组患者治疗效果,比较治疗前后2组炎症因子肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)及神经元特异性烯醇化酶(NSE)、神经肽Y (NPY)变化。 结果 观察组患者治疗总有效率为89.80%,对照组治疗总有效率为79.59%,2组患者治疗总有效率差异无统计学意义(P>0.05);2组患者治疗后炎症因子IL-6、TNF-α水平均明显降低(P<0.05),且观察组患者降低更显著(P<0.05);2组患者治疗后NSE均较治疗前显著降低(P<0.05),NPY均较治疗前显著升高(P<0.05),且观察组变化更显著(P<0.05);观察组患者不良反应率为24.49%,对照组患者不良反应率为32.65%,2组患者治疗不良反应率差异无统计学意义(P>0.05)。 结论 艾司西酞普兰与舍曲林治疗脑卒中后抑郁患者均疗效可靠,不良反应均轻微,但艾司西酞普兰对炎症因子IL-6、TNF-α及NSE、NPY水平的改善效果更好。Abstract: Objective Post-stroke depression was a serious threat to patient safety, which not only increased stroke symptoms, but also increased the patients' mental anguish. In order to reduce the patient's depressive symptoms, and to enhance the effect of prognosis to discover better drug treatment is very important. Thus, the effect of escitalopram and sertraline on inflammatory factors, NSE and NPY was investigated in patients with post-stroke depression in this study. Methods A total of 98 patients with post-stroke depression were divided into control group (49 cases) and observation group (49 cases). The patients in 2 groups received the conventional therapy, and patients in control group were additionally given sertraline therapy, and patients in observation group were additionally given escitalopram therapy. The treatment time was 8 weeks in 2 groups. To observe clinical effect, and effect of treatment on inflammatory factors (TNF-α and IL-6), NSE and NPY were compared before and after treatment in 2 groups. Results Total effective rate of observation group was 89. 80%, total effective rate of control group was 79. 59%, and there was no significant difference between observation group and control group (P > 0. 05). Compared with those before treatment, the levels of TNF-α and IL-6 decreased significantly at 8 weeks after treatment in 2 groups (P < 0. 05), and the levels of TNF-α and IL-6 of observation group decreased more significantly than those in control group (P < 0. 05). Compared with that before treatment, the level of NSE decreased significantly at 8 weeks after treatment in 2 groups (P < 0. 05), the level of NPY increased significantly at 8 weeks after treatment in 2 groups (P < 0. 05), and the changes of NSE and NPY of observation group were significantly more than those in control group (P < 0. 05). Incidence of adverse reactions of observation group was 24. 49%, incidence of adverse reactions of control group was 32. 65%, and incidence of adverse reactions had no significant difference in two groups (P > 0. 05). Conclusion Treatment with escitalopram and sertraline has reliable efficacy with mild adverse reactions, but escitalopram has better effect on IL-6, TNF-α, NSE and NPY in patients with post-stroke depression.
-
Key words:
- Escitalopram /
- Sertraline /
- Post-stroke depression /
- Inflammatory factors /
- Neuron-specific enolase /
- Neuropeptide Y
点击查看大图
计量
- 文章访问数: 121
- HTML全文浏览量: 30
- PDF下载量: 1
- 被引次数: 0